Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

s set out in the New Articles.  The Directors consider the Deferred Shares so created to be of no economic value.  The Deferred Shares will, subject to Shareholder approval pursuant to Resolution 9 of the Resolutions, be repurchased by the Company in accordance with the New Articles for one pence in aggregate and, following such repurchase, shall be cancelled.  The repurchase of the Deferred Shares will be financed out of the proceeds of the issue of the New Ordinary Shares.

The Share Capital Reorganisation will enable the Company to issue and allot shares at a price below the former nominal value of the Ordinary Shares.

No certificates will be sent to Shareholders in respect of the Share Capital Reorganisation, as Shareholder holdings will not change.

Future Activities

During the last 12 months Silence has made progress in advancing its pipeline, capitalising on its RNAi drug delivery capabilities through research collaborations with third parties and in strengthening its intellectual property. In addition, Silence' licensee Quark Pharmaceuticals Inc. has continued to make progress with its clinical programmes which are based on Silence' AtuRNAi technology. The Company is now focused on creating value by making further advances in all aspects of the business.

Atu027

Atu027, for the treatment of solid tumours, is Silence' most advanced internal drug candidate. Atu027 combines Silence' proprietary drug delivery system AtuPLEX with AtuRNAi, the Company's proprietary RNAi chemistry. Atu027 specifically targets PKN3, a protein implicated in cancer growth and metastases. Pre-clinical studies have indicated that Atu027 works by inhibiting blood supply to solid tumours and has a particular profound impact on the prevention and growth of metastases. Combination with other currently marketed anti-cancer drugs has demonstrated additive effects in pre-clinical studies.

Silence is currently conducting a Phase I tri
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Earth, MN (PRWEB) June 19, 2013 ... of abuse tests, today announced that it has received ... to market and sell its DrugCheck® NxStep Onsite ... allows use of the rapid screening device in near-patient ... Onsite Drug Screen Cup received Health Canada Class III ...
(Date:6/18/2013)... 18, 2013 Tabletop SEMs are inexpensive ... but have limited performance and capability such as small ... SEMs would normally provide better imaging performance and more ... and have a higher cost of maintenance. The ... between these two types of SEM product, offering competitive ...
(Date:6/18/2013)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing, ... unaudited financial results for the fourth quarter and full ... Fourth Quarter of Fiscal 2013 Highlights ... 2013 increased by 33.3% to RMB133.0 million ($21.4 million) ...
(Date:6/18/2013)... Los Angeles, CA (PRWEB) June 18, 2013 (PRWEB) ... of construction’s #1 time and attendance system in ... transfer software that shares employee data and payroll ... , AccountLinx Plus automates ExakTime software ... applications. The software imports employee data from a ...
Breaking Biology Technology:Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13ExakTime Introduces AccountLinx Plus 2
... System and GE Medical Systems recently signed a five-year ... medical field. The Wheaton Franciscan System, a Catholic heath ... GE Medical System s Performance Solutions; a portfolio ... care customers in addition to the purchase of imaging ...
... Wis. -- Bruker AXS Inc., a provider of X-ray ... that it has been selected to participate in the ... The project is half-funded by the Dutch government, and ... expects to receive approximately $950,000 in matching funds. ...
... , a provider of integrated data solutions for ... Friday. The service allows customers to meet with ... and other online collaborations. , ,Norlight's Guardian ... visual benefits of Web collaboration. Using a Web-based ...
Cached Biology Technology:
(Date:6/17/2013)... may help delay early onset of puberty in girls, ... Monday at The Endocrine Society,s 95th Annual Meeting in ... the ages of 10 and 14. Boys undergo these ... age. Precocious puberty is diagnosed in girls when sexual ... it is diagnosed when these changes occur before age ...
(Date:6/17/2013)... be the topics under discussion during the E3 ... third consecutive year, this will be a unique ... among members of Academy, Business, Educators, Entrepreneurs, Innovators, ... Elisa Martn Garijo (IBM South Europe), Chris Zegras ... O,Donovan (Hovione), among others. E3 Forum - Education, ...
(Date:6/16/2013)... for female sex workers in India reduce rates of ... University of Toronto study has found. , ... in the southern states of Andhra Pradesh, Karnataka, Maharashtra ... Jha from U of T,s Dalla Lana School of ... Health Research (CGHR), examined the impact of prevention among ...
Breaking Biology News(10 mins):Vitamin D supplementation may delay precocious puberty in girls 2'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2HIV prevention among female sex workers in India reduces HIV and syphilis 2
... Thomas C. Quinn, M.D., a Johns Hopkins physician and scientist, ... years leading major efforts to combat HIV and AIDS throughout ... confront the rapid "feminization" of the AIDS pandemic. , Quinn, ... investigator at the National Institute of Allergy and Infectious Disease, ...
... people, naturally produce disease-fighting chemicals, called antimicrobial peptides, ... some disease-causing bacteria have evolved antimicrobial detectors. The ... a warning signal. This alarm sets off a ... University of Washington (UW) and McGill University researchers ...
... of the three-dimensional terrain of a synapse -- the ... the brain and nervous system. The "nano-map," which shows ... or one-billionth of a meter, has already proven its ... , Using the map as a guide, the research ...
Cached Biology News:AIDS expert says global strategy needed to combat feminization of HIV/AIDS 2AIDS expert says global strategy needed to combat feminization of HIV/AIDS 3Bacteria recognize antimicrobials, respond with counter-defenses 2The synapse is a shotgun 2The synapse is a shotgun 3
...
... potent inhibition of RNase A-type ribonucleases Product ... of nonhuman origin that binds noncovalently and ... A, B, and C). It does not ... U2, or CL3. QIAGEN RNase Inhibitor inhibits ...
...
... Radiochemical Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
Biology Products: